Free Trial

Vivos Therapeutics Q4 2022 Earnings Report

Vivos Therapeutics logo
$3.12 -0.17 (-5.17%)
As of 02/21/2025 04:00 PM Eastern

Vivos Therapeutics EPS Results

Actual EPS
-$5.00
Consensus EPS
-$5.50
Beat/Miss
Beat by +$0.50
One Year Ago EPS
N/A

Vivos Therapeutics Revenue Results

Actual Revenue
$3.95 million
Expected Revenue
$4.01 million
Beat/Miss
Missed by -$60.00 thousand
YoY Revenue Growth
N/A

Vivos Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Vivos Therapeutics Earnings Headlines

Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Vivos Therapeutics files $50M mixed securities shelf
Vivos to sell 709,220 shares at $4.935 in registered direct offering
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS), a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

View Vivos Therapeutics Profile

More Earnings Resources from MarketBeat